Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.48 |
| ▸ | DNM2 | P50570 | 4/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639082 | 0.82 | POLB (0.45) | HCAR3NPC1ALDH1A1 | |
| SCHEMBL28018371 | 0.79 | NPC1 (0.49) | TLR8DNM2HCAR3NPC1TLR7 | |
| SCHEMBL16019053 | 0.78 | TLR8 (0.46) | TLR8DNM2HCAR3KCNH3 | |
| SCHEMBL31648525 | 0.77 | TLR8 (0.49) | TLR8DNM2HCAR3KCNH3SOAT1 | |
| SCHEMBL1234357 | 0.76 | NCF1 (0.55) | TLR8DNM2NPC1KCNH3BCHE | |
| SCHEMBL28260563 | 0.75 | TLR8 (0.45) | TLR8NPC1TLR7KCNH3ASAH1 | |
| SCHEMBL516003 | 0.75 | TLR8 (0.51) | TLR8DNM2HCAR3NPC1KCNH3 | |
| SCHEMBL6129289 | 0.74 | KCNH2 (0.55) | ALDH1A1 | |
| SCHEMBL30449687 | 0.74 | CYP2C19 (0.59) | TLR8HCAR3SOAT1ALOX12 | |
| SCHEMBL515358 | 0.74 | CYP2C19 (0.59) | TLR8HCAR3SOAT1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669544-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20190264207-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-10273477-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-1620544-B1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-1605978-A2 | THERAPEUTIC COMPOSITIONS | Alnylam Pharmaceuticals Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050233342-A1 | Methods of preventing off-target gene silencing | ALNYLAM PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050186591-A1 | Method of treating neurodegenerative disease | ALNYLAM PHARMACEUTICALS | 2005-08-25 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | TLR8 591/4885DNM2 1922/4885HCAR3 2112/4885 |
| US-10273477-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | TLR8 1937/4885DNM2 643/4885HCAR3 3592/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | TLR8 666/4885DNM2 1654/4885HCAR3 2293/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | TLR8 666/4885DNM2 1654/4885HCAR3 2293/4885 |
| US-20190264207-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | TLR8 1937/4885DNM2 643/4885HCAR3 3592/4885 |
| US-20050186591-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | TLR8 4390/4885DNM2 68/4885HCAR3 3760/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | TLR8 1937/4885DNM2 643/4885HCAR3 3592/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | TLR8 666/4885DNM2 1654/4885HCAR3 2293/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | TLR8 1937/4885DNM2 643/4885HCAR3 3592/4885 |
| US-10669544-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | TLR8 1937/4885DNM2 643/4885HCAR3 3592/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | TLR8 422/4885DNM2 2372/4885HCAR3 1235/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | TLR8 666/4885DNM2 1654/4885HCAR3 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.